For the almost 520,000 Americans who will undergo treatment this year, the process leaves little room for a full life. An innovative new device could change everything.
A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...
This partnership aims to integrate Stamicarbon’s proprietary NX STAMI Urea technology and Diesel Exhaust Fluid (DEF) production systems, setting a new benchmark for sustainable agriculture in Western ...